Henlius falls short of IPO goal, but still rakes in $410M on HKEX

hong kong
The company earmarked 40% of the proceeds for the clinical development, regulatory filing and registration of its “Core Products,” which include biosimilars for the cancer drugs Herceptin and Avastin. (Pixabay)

Last week, Shanghai Henlius Biotech teed up for a $477 million IPO on the Hong Kong Stock Exchange. It fell a little short when it priced on Wednesday, ultimately bagging $410 million, but still made the top five biopharma IPOs so far this year. 

It is Hong Kong’s first major listing since that of Jinshang Bank in July, according to Bloomberg, and the first biopharma listing since Hansoh’s $1 billion debut in June. Henlius’ debut also comes amid antigovernment protests over an extradition bill that has since been withdrawn.

The company earmarked 40% of the proceeds for the clinical development, regulatory filing and registration of its “Core Products,” according to a filing with the HKEX. These include HLX02, a Herceptin biosimilar in phase 3 and HLX04, an Avastin biosimilar in phase 3 for metastatic colorectal cancer. Henlius is also testing HLX04 in combination with HLX10, an anti-PD-1 antibody, in non-small cell lung cancer and liver cancer. 

Webinar

CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

RELATED: Atomwise takes on 2 more JVs, including a $1.5B project with China's Hansoh Pharma 

The rest of the proceeds will support the development of other biosimilars, as well as drug programs discovered at Henlius, including those targeting VEGF, EGFR and PD-L1. 

“We are currently conducting clinical trials of HLX06, HLX07, HLX10 and HLX20 and will further explore immuno-oncology combination therapies using immune checkpoint inhibitor such as PD-1/PD-L1 drugs,” Henlius said in the filing.

“We believe that the successful development and commercialisation of these products and therapies are key to our long-term sustainable development following the expected launch of our Core Products. As all of our CoreProducts have reached late-stage development in Phase 3 clinical trials or later, we believe that it is reasonable to allocate a significant portion of the expected net proceeds to the development of our other pipeline products and therapies,” the company said.

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections with potential results in about a half-hour.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.